Pfizer Amends 13D Filing on Longboard Pharmaceuticals Stake

TL;DR

**Pfizer updated its stake in Longboard, signaling continued oversight.**

AI Summary

Pfizer Inc. filed an Amendment No. 3 to its Schedule 13D on January 25, 2024, regarding its ownership in Longboard Pharmaceuticals, Inc. This filing updates previous disclosures about Pfizer's stake in Longboard's Common Stock, par value $0.0001 per share. This matters to investors because it provides transparency into a major pharmaceutical company's continued involvement and influence over a smaller, specialized drug developer, which could signal future strategic moves or divestitures.

Why It Matters

This filing indicates Pfizer's ongoing reporting obligations and potential strategic interest in Longboard Pharmaceuticals, which could impact Longboard's stock valuation and future direction.

Risk Assessment

Risk Level: low — This is an informational update filing and does not inherently present new risks, but rather clarifies existing ownership structures.

Analyst Insight

Investors should note Pfizer's continued reporting on its Longboard stake, but this specific filing is purely administrative. Further amendments or other filings would be needed to infer any new strategic actions.

Key Players & Entities

• Pfizer Inc. (company) — the filing person and reporting entity
• Longboard Pharmaceuticals, Inc. (company) — the subject company whose securities are being reported
• Margaret M. Madden, Esq. (person) — Senior Vice President and Corporate Secretary, Chief Governance Counsel for Pfizer Inc.
• DLA Piper LLP (US) (company) — legal counsel for Pfizer Inc.
• $0.0001 (dollar_amount) — par value per share of Longboard Pharmaceuticals' Common Stock

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie
• $24.25 — ommon Stock directly held at a price of $24.25 per share before fees and no longer hol

Filing Documents

• sch13dalongboard124x.htm (SC 13D/A) — 62KB
• 0000078003-24-000015.txt ( ) — 64KB

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer The following amends and restates the information set forth in the first paragraph of Item 5 of the Statement, captioned "(a)—(b)" in its entirety. (a)—(b) As of the date of the Statement, as amended by Amendment No. 3, the Reporting Persons holds nil shares of Common Stock, representing 0.00% of the outstanding shares of Common Stock. The following amends and restates the information set forth in the fourth paragraph of Item 5 of the Statement, captioned "(c)" in its entirety. (c) On January 25, 2024, Arena sold all 3,978,540 shares of Common Stock directly held at a price of $24.25 per share before fees and no longer holds any shares of the Issuer. (e) On January 25, 2024, the Reporting Persons ceased to be the beneficial owner of more than five percent of the Shares. The filing of this Amendment No. 3 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons. CUSIP NO 54300N103 Page 5 of 5

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated January 29, 2024 PFIZER INC. By s Susan Grant Name Susan Grant Title Assistant Secretary ARENA PHARMACEUTICALS, INC. By s Susan Grant Name Susan Grant Title Assistant Secretary

View Full Filing

View this SC 13D/A filing on SEC EDGAR